Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial
The Lancet Infectious Diseases（2022）
摘要
Novavax and the Coalition for Epidemic Preparedness Innovations.
更多查看译文
关键词
recombinant spike protein vaccine,homologous booster dose,immunogenicity,sars-cov,nvx-cov,placebo-controlled
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要